EL7.AI
StocksMediumUpdated•Originally published 3 November 2026•Updated 3 November 2026•
1 min read

Rhythm Pharmaceuticals Revenue Surges 29% in Q3 2026 on Strong IMCIVREE Sales

Key Facts

1Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, a 29% increase from the prior quarter.
2Patient start forms for IMCIVREE in hypothalamic obesity exceeded 700 as of September 30, 2026.

Rhythm Pharmaceuticals reported Q3 2026 net product revenue of $92.1 million, marking a 29% increase from the previous quarter. According to a statement released via GlobeNewswire, the revenue growth was driven by strong U.S. launch momentum for IMCIVREE in hypothalamic obesity and the start of its commercial rollout in Japan.

Patient start forms for IMCIVREE exceeded 700 as of September 30, 2026, indicating robust uptake for the obesity treatment. In equity markets, RYTM closed at $93.44 on November 2, 2026, having traded between a session low of $92.4 and a high of $95.35.

Latest Updates · 1

  1. Major·

    Update: Rhythm Pharmaceuticals secured a $750 million term-loan facility from KKR and Blackstone on November 3, 2026. The company also amended its licensing agreement for bivamelagon with LG Chem alongside the financing deal.

Open on chart